drugset / Trial / NCT03106571

Study of Pomaglumetad and Methamphetamine

NCT03106571

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is the first study of pomaglumetad in humans using methamphetamine. The goal of the study is to determine if pomaglumetad is safe when administered with methamphetamine. If shown to be safe with methamphetamine in the current study, a phase 2 clinical trial of pomaglumetad would be done to begin to find out if pomaglumetad is effective in treating methamphetamine use disorder.

Timeline

Start
2017-08-01
Primary completion
2020-07-31
Completion
2020-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject LY404039 Small molecule 40 mg Oral
Subject LY404039 Small molecule 80 mg Oral
Subject LY404039 Small molecule 160 mg Oral
Subject Methamphetamine Small molecule 30 mg Intravenous